UCB Announces Breakthrough Data on KYGEVVI Therapy for Rare Genetic Disorder TK2d.1

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI in Patients with Thymidine Kinase 2 Deficiency (TK2d). The data shows that KYGEVVI therapy improved survival and functional outcomes in people with TK2d, marking a significant milestone for the treatment of this rare genetic disorder.